Aytu BioPharma Statistics
Share Statistics
Aytu BioPharma has 6.17M
shares outstanding. The number of shares has increased by 3.31%
in one year.
| Shares Outstanding | 6.17M |
| Shares Change (YoY) | 3.31% |
| Shares Change (QoQ) | 0.33% |
| Owned by Institutions (%) | 0.15% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 298 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 740.35K, so 12% of the outstanding
shares have been sold short.
| Short Interest | 740.35K |
| Short % of Shares Out | 12% |
| Short % of Float | 17.28% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -1 and the forward
PE ratio is 1.32.
Aytu BioPharma's PEG ratio is
0.02.
| PE Ratio | -1 |
| Forward PE | 1.32 |
| PS Ratio | 0.19 |
| Forward PS | 0.1 |
| PB Ratio | 0.57 |
| P/FCF Ratio | -11.37 |
| PEG Ratio | 0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Aytu BioPharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.99,
with a Debt / Equity ratio of 0.55.
| Current Ratio | 0.99 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | -14.95 |
| Debt / FCF | -10.9 |
| Interest Coverage | -1.1 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $794,137.25 |
| Profits Per Employee | $-155,333.33 |
| Employee Count | 102 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.09 |
Taxes
| Income Tax | 1.77M |
| Effective Tax Rate | -12.56% |
Stock Price Statistics
The stock price has increased by -50.79% in the
last 52 weeks. The beta is 0.05, so Aytu BioPharma's
price volatility has been higher than the market average.
| Beta | 0.05 |
| 52-Week Price Change | -50.79% |
| 50-Day Moving Average | 1.36 |
| 200-Day Moving Average | 1.72 |
| Relative Strength Index (RSI) | 46.54 |
| Average Volume (20 Days) | 1,201,946 |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of 81M
and earned -15.84M
in profits. Earnings per share was -2.86.
| Revenue | 81M |
| Gross Profit | 54.59M |
| Operating Income | -5.25M |
| Net Income | -15.84M |
| EBITDA | -1.01M |
| EBIT | -9.28M |
| Earnings Per Share (EPS) | -2.86 |
Full Income StatementBalance Sheet
The company has 20.01M in cash and 15.13M in
debt, giving a net cash position of 4.88M.
| Cash & Cash Equivalents | 20.01M |
| Total Debt | 15.13M |
| Net Cash | 4.88M |
| Retained Earnings | -319.97M |
| Total Assets | 124.2M |
| Working Capital | 1.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -1.39M
and capital expenditures 0, giving a free cash flow of -1.39M.
| Operating Cash Flow | -1.39M |
| Capital Expenditures | n/a |
| Free Cash Flow | -1.39M |
| FCF Per Share | -0.25 |
Full Cash Flow StatementMargins
Gross margin is 67.39%, with operating and profit margins of -6.49% and -19.56%.
| Gross Margin | 67.39% |
| Operating Margin | -6.49% |
| Pretax Margin | -17.38% |
| Profit Margin | -19.56% |
| EBITDA Margin | -1.25% |
| EBIT Margin | -6.49% |
| FCF Margin | -1.71% |
